Latest News

Thursday, September 14, 2017 | Product Releases

New Medical Marketing Agency Launches

A new health care and medical device marketing agency, Biotica, has launched in Cincinnati. Partners Bill Abramovitz, Susan Abramovitz, and Ben Singleton created Biotica to serve national and inte…

Read the full story

Thursday, September 14, 2017 | Awards

ASCRS Foundation Announces New Chang Humanitarian Award

The American Society of Cataract & Refractive Surgery (ASCRS) Foundation is pleased to announce the creation of the ASCRS Foundation Chang Humanitarian Award. This annual award, which is endowed b…

Read the full story

Thursday, September 14, 2017 | Product Releases

LensFerry Now Offers EHR Integration; Automation Drives Practice Revenue

The digital age has fundamentally changed the marketplace with US online contact lens sales totaling almost $700 million. Giving patients a seamless way to buy lenses from their doctor has become more…

Read the full story

Thursday, September 14, 2017 | Product Releases

Plusoptix Announces the Launch of Its Latest Innovative Vision Screening Device for Pediatric Clinics

Plusoptix announced the launch of its new plusoptiX S16 series, a vision screening device developed especially for the use in pediatric clinics. The plusoptiX S16 is designed to enable pediatricians t…

Read the full story

Wednesday, September 13, 2017 | Health Care

FDA Quality Pilot Aims to Streamline Device Review Process

The FDA is piloting a new scheme for high-risk medical devices that removes the need for preapproval inspections in return for making more information on device quality available early on, according…

Read the full story

Wednesday, September 13, 2017 | Acquisitions/Mergers, Inotek Pharmaceuticals

Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals

Inotek Pharmaceuticals have entered into a definitive merger agreement with Rocket Pharmaceuticals, a US-based gene therapy company. Subject to shareholder approval, the combined company will retain t…

Read the full story

Wednesday, September 13, 2017 | Product Releases, Optovue

Optovue Unveils New AngioVue Essential OCTA at the International Vision Expo

Optovue debuted its AngioVue Essential OCTA capability for optometry and general ophthalmology at the International Vision Expo & Conference 2017 in Las Vegas. AngioVue Essential aids clinician…

Read the full story

Tuesday, September 12, 2017 | Acquisitions/Mergers, PhysIOL sa

PhysIOL Acquires a Majority Stake in Optikon

PhysIOL announced that it has entered into a definitive agreement under which PhysIOL will acquire a majority stake in opthalmic device manufacturer Optikon. Terms of the deal were not disclosed. I…

Read the full story

Tuesday, September 12, 2017 | Medical Studies

OCT Screening Cost-Effective for Diabetic Retinopathy

The use of optical coherence tomography (OCT) to screen everyone with diabetes for retinopathy appears to be a relatively inexpensive way to preserve the quality of life of these patients, results fro…

Read the full story

Monday, September 11, 2017 | Acquisitions/Mergers, Alphaeon

Strathspey Crown to Acquire ShoutMD From Alphaeon Corporation

Strathspey Crown Holdings announced that it has reached an agreement in principle with Alphaeon to acquire the ShoutMD social media platform in its entirety, includi…

Read the full story

Monday, September 11, 2017 | Corporate Lawsuits, Imprimis Pharmaceuticals

Imprimis Releases Statement Regarding Allergan Lawsuit

Imprimis Pharmaceuticals responded to a press release issued by Allergan regarding a lawsuit Allergan USA filed against Imprimis. A portion of the Imprimis statement reads: "Imprimis will aggr…

Read the full story

Monday, September 11, 2017 | Retina, Alimera Sciences

Illuvien Now Available in Ireland for the Treatment of Chronic DME

Iluvien (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) is being made available in Ireland following an agreement between the healthcare provider Vhi and Iluvien’s …

Read the full story

Monday, September 11, 2017 | Clinical Trials,Retina, AMD, Genentech

Genentech's Lampalizumab Fails Phase 3 Study for Geographic Atrophy

Genentech announced that the primary endpoint has not been met in Spectri, the first of two phase 3 studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the trea…

Read the full story

Monday, September 11, 2017 | Medical Studies,Retina

Ranibizumab Beats Laser for Diabetic Retinopathy

Ranibizumab treats proliferative diabetic retinopathy more effectively than laser photocoagulation, researchers reported at the 17th EURETINA Congress. The finding challenges lasers as the standard of…

Read the full story

Monday, September 11, 2017 | Medical Studies,Retina

Retina Specialists Seek to Stem Myopia Epidemic

In light of the increasing prevalence of myopia in certain parts of the world, ophthalmologists should advise parents on ways to curb the development of myopia in children and intervene early if myopi…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $60.10  3.09% 
 Akorn, Inc. $33.02  -0.24% 
 Alimera Sciences, Inc. $1.38  2.22% 
 Allergan $221.54  0.57% 
 Applied Genetic Technologies $3.75  5.63% 
 Bayer $132.42  0.43% 
 Can-Fite Biopharma $1.73  -0.57% 
 Carl Zeiss Meditec $42.30  0.09% 
 Clearside Biomedical $7.60  0.00% 
 Cooper Companies, Inc. $249.11  1.59% 
 Eleven Biotherapeutics $1.45  7.41% 
 Escalon Medical Corp. $0.12  0.00% 
 Essilor International $106.15  0.14% 
 Glaukos $32.16  2.42% 
 Imprimis Pharmaceuticals, Inc. $1.67  -4.57% 
 Inotek Pharmaceuticals $1.31  0.00% 
 IRIDEX Corporation $9.87  1.75% 
 Johnson & Johnson $135.38  0.69% 
 Luxottica Group, S.p.A. $60.90  0.41% 
 Merck & Company, Inc. $65.99  -0.26% 
 NicOx $9.50  0.85% 
 NovaBay Pharmaceuticals, Inc. $4.35  8.75% 
 Novartis AG Common Stock $85.11  -0.55% 
 Ocular Therapeutix $6.28  -3.24% 
 Ophthotech Corporation $2.52  0.00% 
 Quantel $6.64  2.15% 
 Regeneron $434.64  0.27% 
 Roche $31.57  -0.47% 
 Second Sight Medical Products $1.15  2.68% 
 Shire $155.66  -1.77% 
 STAAR Surgical Company $11.30  0.89% 
 TearLab Corporation $1.41  2.17% 
 Thrombogenics $3.80  -3.38% 
 Valeant Pharmaceuticals $13.79  -0.93% 
 Xoma $19.09  -1.60%